Industry Shakeup: Bluesight's Acquisition of Protenus and What It Means for Customers

Industry Shakeup: Bluesight's Acquisition of Protenus and What It Means for Customers

Terri Vidals, a seasoned pharmacist, takes centre stage in this episode of 'Drug Diversion Insights'. With over three decades in the healthcare industry, Terri shares her perspective on a major shakeup involving Bluesight's acquisition of Protenus. For those unfamiliar with the buzz, this merger has left Protenus customers in a bit of a pickle. They were quite content with their existing software solutions and price points, but now face a transition to Bluesight's platform, which isn't exactly a bargain.

Terri dives into the heart of this matter, exploring how customers are managing negotiations with Bluesight amidst this unexpected change. She brings to light the frustrations of customers who must suddenly shift gears, all while grappling with higher costs and new contracts. It's like being told you have to swap your favourite comfy shoes for a pair that pinches your toes - not the most pleasant surprise.

Throughout the episode, Terri reflects on the industry's rapid consolidation and what it means for those navigating these waters. Despite the reluctance of some to speak out publicly due to ongoing negotiations, Terri candidly shares what she's hearing from insiders. This episode is a treasure trove of insights for anyone in healthcare compliance technology. So, why should you tune in?

If you're curious about the ripple effects of this acquisition and want to understand the broader implications for healthcare compliance, Terri's analysis provides clarity. Whether you're directly impacted or simply interested in industry dynamics, there's something here for everyone.